Share on LinkedInShare on LinkedIn

ARTICLE · 30 JULY 2026

Prediction Markets Meet Pharma

Steptoe LLP
Steptoe LLP
Contributor
Steptoe LLP

Steptoe LLP

Steptoe International (UK) LLP has built a strong reputation for providing top-quality regulatory,...

View firm profile
Explore more from Steptoe LLP

Kalshi's launch of prediction markets for clinical trial outcomes and FDA decisions introduces novel compliance challenges at the intersection of pharmaceutical regulation and securities law. As enforcement actions in the life sciences sector demonstrate persistent scrutiny of insider trading, pharmaceutical companies must now address how prediction market participation by employees could create new risks around material nonpublic information and clinical trial integrity. Legal and compliance frameworks wil

United StatesFinance and Banking

On July 16, Kalshi announced the launch of a new prediction market platform focused on clinical trial outcomes and FDA regulatory decisions through a partnership with AppliedXL,1 an AI-driven information and analytics company that analyzes public data to produce forecasting insights. The pilot program is currently limited to late-stage clinical trials. Contracts are listed only after patient enrollment has closed, and traders are subject to employment verification requirements to ensure they are not employed by any of the companies involved in the clinical trials. Kalshi also states that, as with its other markets, individuals in possession of material nonpublic information are prohibited from trading.2

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from